Drug Trial Radar · NCT07241923
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection
Last checked: Nov 20, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Nov 15, 2025
Primary completion
Nov 1, 2026
Study completion Nov 1, 2027
Sponsor
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2070 injection when administered subcutaneously to healthy subjects.
Conditions
- Healthy Subjects (HS)
Interventions
SYH2070 injectionDrug
subcutaneous injection
PlaceboDrug
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects with Adverse Events as Assessed by CTCAE v5.0Time frame: Pre-dose and multiple time points no less than 85 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trials Information Group
Shijiazhuang, Hebei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.